BACLOFEN INJECTION 2 MG — DIN 02457075
BACLOFEN : 2 MG · HIKMA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is BACLOFEN INJECTION?
BACLOFEN INJECTION 2 MG contains BACLOFEN : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02457075, held by HIKMA CANADA LIMITED, supplied as SOLUTION for INTRATHECAL administration. Health Canada currently lists it as marketed, status dated 26-May-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BACLOFEN INJECTION used for?
Baclofen Injection is indicated for the management of patients with severe spasticity due to spinal cord injury or multiple sclerosis who are unresponsive to oral baclofen or who experience unacceptable side effects at effective oral doses. Baclofen Injection therapy may be considered as an alternative to destructive neurosurgical procedures. Prior to implantation of a device for chronic intrathecal infusion, patients must demonstrate a positive clinical response to a Baclofen Injection screening trial. Baclofen Injection has been used in patients with other spasticity of cerebral origin, e.g. spasticity following hypoxic encephalopathy, head injury, or stroke; however, clinical experience is limited.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Baclofen cost around the world?
Baclofen is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 7 | 127 | USD███.██ |
| Australia | ex-manufacturer | 10 | 24 | AUD███.██ |
| Saudi Arabia | public | 11 | 14 | SAR███.██ |
| South Africa | single exit price | 12 | 13 | ZAR███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| Bahrain | retail (max) | 4 | 6 | BHD███.██ |
| Greece | producer price (ex-factory) | 5 | 5 | EUR███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| Hungary | producer price (ex-factory) | 4 | 4 | HUF███.██ |
| Romania | max producer price | 2 | 4 | RON███.██ |
208 pack listings across 66 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Baclofen pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Baclofen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
25 holders have a Canadian DIN containing Baclofen, across 59 DINs, of which 23 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 3 | 3 | BACLOFEN INJECTION USP, JAMP BACLOFEN | Sourceable in Canada |
| STERIMAX INC | 3 | 3 | BACLOFEN INJECTION | Sourceable in Canada |
| APOTEX INC | 4 | 2 | APO-BACLOFEN, BACLOFEN | Sourceable in Canada |
| AVIR PHARMA INC. | 3 | 2 | BACLOFEN INTRATHECAL | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 2 | 2 | RIVA-BACLOFEN | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 2 | 2 | MYLAN-BACLOFEN | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 2 | PMS-BACLOFEN | Sourceable in Canada |
| PRO DOC LIMITEE | 2 | 2 | PRO-BACLOFEN | Sourceable in Canada |
| SANIS HEALTH INC | 2 | 2 | BACLOFEN | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 2 | 2 | BACLOFEN | Sourceable in Canada |
| HIKMA CANADA LIMITED | 3 | 1 | BACLOFEN INJECTION | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 5 | 0 | LIORESAL D.S. TAB 20MG, LIORESAL INTRATHECAL 0.05MG/ML, LIORESAL INTRATHECAL 0.5MG/ML, LIORESAL INTRATHECAL 2MG/ML, LIORESAL TAB 10MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRATHECAL |
| Pack configuration (monograph) | 0.05 mg/mL: cartons of 10 ampoules; 0.5 mg/mL: cartons of 1 ampoule; 2 mg/mL: cartons of 10 ampoules (5 mL ampoule), cartons of 1 ampoule (20 mL ampoule) |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Baclofen |
|---|---|
| ATC code | M03BX01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02457075 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2457075 |
| Brand name | BACLOFEN INJECTION |
| Generic / active ingredient | BACLOFEN : 2 MG |
| Market authorization holder | HIKMA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | M03BX01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M03BX |
| Current status | MARKETED |
| Status date | 26-May-2023 |
| Original market date | 2016-09-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Baclofen in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by AVIR PHARMA INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
23 of 59 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BACLOFEN | 10 MG | TABLET | APOTEX INC | MARKETED | 02139332 |
| APO-BACLOFEN | 20 MG | TABLET | APOTEX INC | MARKETED | 02139391 |
| BACLOFEN | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | 02287021 |
| BACLOFEN | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | 02287048 |
| BACLOFEN | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02544660 |
| BACLOFEN | 20 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02544679 |
| BACLOFEN INJECTION | 10 MG / 5 ML | SOLUTION | STERIMAX INC | MARKETED | 02413647 |
| BACLOFEN INJECTION | 0.05 MG / 1 ML | SOLUTION | STERIMAX INC | MARKETED | 02413620 |
| BACLOFEN INJECTION | 10 MG / 20 ML | SOLUTION | STERIMAX INC | MARKETED | 02413639 |
| BACLOFEN INJECTION USP | 2 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02553341 |
2 · Same class — other molecules in ATC M03BX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Baclofen | APO-BACLOFEN · AVA-BACLOFEN · BACLOFEN · BACLOFEN INJECTION · +29 more | 59 | 23 | Yes |
| Cyclobenzaprine | AG-CYCLOBENZAPRINE · ALTI-CYCLOBENZAPRINE - TAB 10MG · APO-CYCLOBENZAPRINE · AURO-CYCLOBENZAPRINE · +15 more | 23 | 10 | Yes |
| Tizanidine | APO-TIZANIDINE · MINT-TIZANIDINE · MYLAN-TIZANIDINE · PAL-TIZANIDINE | 5 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M03B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M03BA | Methocarbamol · Methocarbamol, Combinations Excl Psycholeptics | 76 | 14 |
| M03BC | Orphenadrine (Citrate) · Orphenadrine, Combinations | 7 | 1 |
| M03BB | Chlorzoxazone, Combinations Excl Psycholeptics | 8 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BACLOFEN INJECTION called?
The same molecule, Baclofen, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Baclofen | Latin | Australia |
| Baclon | Latin | Bahrain, Saudi Arabia |
| Sintetica Baclofen Intrathecal | Latin | Australia |
| BACLOCALM | Latin | Bahrain |
| Bacthecal | Latin | Australia |
| Bastix | Latin | Saudi Arabia |
| Lioresal | Latin | Bahrain, South Africa |
| Lioresal Intrathecal | Latin | Australia |
| Loanta | Latin | Bahrain, Saudi Arabia |
| baclocan | Latin | Saudi Arabia |
| Baclofen | Latin | Saudi Arabia |
| Baclofen Crescent | Latin | Saudi Arabia |
| Bio-Baclofen | Latin | South Africa |
| Fenozyd | Latin | South Africa |
| Spasifen | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.